Wade T P, Kraybill W G, Virgo K S, Johnson F E
Department of Surgery, John Cochran Department of Veterans Affairs Medical Center, St. Louis University School of Medicine, Missouri.
J Surg Oncol. 1995 Feb;58(2):104-11. doi: 10.1002/jso.2930580207.
To assess the outcomes after pancreatic cancer treatment in a nationwide hospital system, patients treated in Department of Veterans Affairs (DVA) hospitals from 1987 to 1991 were studied by tumor stage, the most significant reported influence on survival. Tumor registrars from DVA hospitals provided information that allowed TNM staging in 598 patients, and duration of survival from treatment to death was known in 96+% of cases. Survival was 9 months longer after 64 resections for stage I-II (localized) pancreatic cancer than after 149 other treatments (P < 0.05, ANOVA), but resection did not increase mean survival in 49 patients with stage III (lymph node metastases) disease. Twenty-one patients with ampullary, duodenal, bile duct, or cystic cancers had a significantly increased survival at any stage, but this may be due to the selection of sicker patients for nonoperative therapies.
为评估在全国医院系统中胰腺癌治疗后的结果，对1987年至1991年在退伍军人事务部（DVA）医院接受治疗的患者，按照肿瘤分期进行了研究，肿瘤分期是已报道的对生存影响最为显著的因素。DVA医院的肿瘤登记员提供的信息使得598例患者能够进行TNM分期，并且在96%以上的病例中已知从治疗到死亡的生存时间。I-II期（局限性）胰腺癌64例切除术后的生存期比149例其他治疗后的生存期长9个月（P<0.05，方差分析），但在49例III期（淋巴结转移）疾病患者中，切除并未增加平均生存期。21例壶腹癌、十二指肠癌、胆管癌或胆囊癌患者在任何分期的生存期均显著延长，但这可能是由于选择了病情较重的患者进行非手术治疗所致。
